Abstract
Objective: The aim of present study is to develop and explore efficiency of 5.0G EDA PAMAM dendrimers as long-duration drug release carriers for the treatment of tuberculosis.
Method: Rifampicin (RIF) was selected as a major drug for incorporation into PAMAM dendrimers based on its anti-tubercular activity and hydrophobic nature. Further polyethylene glycol (PEGylated) PAMAM dendrimers were evaluated for their hemolytic toxicity and in vivo anti-tubercular studies. The 5.0G PAMAM dendrimers are prepared by using initiator core ethylene diamine and methyl acrylate. Furthermore, the PEGylation was done by polyethylene glycol 2000 using epichlorhydrin as a cross linking agent.
Result: The Rifampicin loaded PEGylated 5.0G PAMAM dendrimers were characterized by FTIR, NMR, DSC and SEM analysis. The in vivo study report ensures the suitability of PEGylated dendrimer in connection to prolonged delivery of Rifampicin. Moreover, PEGylated system has shown a reduced hemolytic toxicity.
Conclusion: The observed results concluded that the PEGylated method was less time consuming, inexpensive, and reproducible, and it also reduces toxicity.
Keywords: PAMAM dendrimers, rifampicin, PEGylation, in vivo PAMAM dendrimers, anti-tubercular studies, hemolytic toxicity.
Current Drug Therapy
Title:Formulation of Rifampicin Loaded PEGylated 5.0G EDA-PAMAM Dendrimers as Effective Long-Duration Release Drug Carriers
Volume: 12 Issue: 2
Author(s): Pandurangan Dineshkumar, Theivendren Panneerselvam*, Kilim Deepti Brundavani, Kunjiappan Selvaraj and Palanirajan Vijayaraj Kumar
Affiliation:
- Department of Pharmaceutical Chemistry, Karavali College of Pharmacy, Vamanjoor, Mangaluru, Karnataka 575028,India
Keywords: PAMAM dendrimers, rifampicin, PEGylation, in vivo PAMAM dendrimers, anti-tubercular studies, hemolytic toxicity.
Abstract: Objective: The aim of present study is to develop and explore efficiency of 5.0G EDA PAMAM dendrimers as long-duration drug release carriers for the treatment of tuberculosis.
Method: Rifampicin (RIF) was selected as a major drug for incorporation into PAMAM dendrimers based on its anti-tubercular activity and hydrophobic nature. Further polyethylene glycol (PEGylated) PAMAM dendrimers were evaluated for their hemolytic toxicity and in vivo anti-tubercular studies. The 5.0G PAMAM dendrimers are prepared by using initiator core ethylene diamine and methyl acrylate. Furthermore, the PEGylation was done by polyethylene glycol 2000 using epichlorhydrin as a cross linking agent.
Result: The Rifampicin loaded PEGylated 5.0G PAMAM dendrimers were characterized by FTIR, NMR, DSC and SEM analysis. The in vivo study report ensures the suitability of PEGylated dendrimer in connection to prolonged delivery of Rifampicin. Moreover, PEGylated system has shown a reduced hemolytic toxicity.
Conclusion: The observed results concluded that the PEGylated method was less time consuming, inexpensive, and reproducible, and it also reduces toxicity.
Export Options
About this article
Cite this article as:
Dineshkumar Pandurangan, Panneerselvam Theivendren*, Brundavani Deepti Kilim , Selvaraj Kunjiappan and Kumar Vijayaraj Palanirajan, Formulation of Rifampicin Loaded PEGylated 5.0G EDA-PAMAM Dendrimers as Effective Long-Duration Release Drug Carriers, Current Drug Therapy 2017; 12 (2) . https://dx.doi.org/10.2174/157488550703160121191905
DOI https://dx.doi.org/10.2174/157488550703160121191905 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Oxidative Stress and Beyond: Multiple Functions of the Protein Glutathionylation
Protein & Peptide Letters Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Effect of Polarization of Ligand Charges and Estimation of MM/GBSA Binding Free Energies of Some Pyrazolo[3,4-d]pyrimidine Inhibitors of Mycobacterium Tuberculosis in View of Experimental Results
Current Enzyme Inhibition The Anemia Prevalence and the Association Between Complete Blood Count Analysis and Renal Function Parameters in HIV-1-Infected Patients
Current HIV Research Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis
Current Protein & Peptide Science Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Structure-based Virtual Screening to Get New Scaffold Inhibitors of the Ser/Thr Protein Kinase PknB from Mycobacterium tuberculosis
Letters in Drug Design & Discovery The Parent-into-F1 Model of Graft-vs-Host Disease as a Model of In Vivo T Cell Function and Immunomodulation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents AMPA Receptor Potentiators as Novel Antidepressants
Current Pharmaceutical Design Formation of Mycobacterial Pellicles In Vitro and their Possible Impact on Tuberculosis Infection
Current Respiratory Medicine Reviews Novel Asthma Therapies: A Review
Current Drug Therapy Anti-Infective Action of Immuno-modulating Polysaccharides (β-Glucan and Plantago Major L. Pectin) against Intracellular (Mycobacteria sp.) and Extracellular (Streptococcus Pneumoniae sp.) Respiratory Pathogens
Current Medicinal Chemistry - Anti-Infective Agents Graphical Abstracts
Letters in Drug Design & Discovery Editorial [Hot topic: Structure-Based Virtual Screening (Guest Editor: Walter Filgueira De Azevedo Jr.)]
Current Drug Targets Editorial (Thematic Issue: New Antimicrobial Therapeutics)
Current Medicinal Chemistry Editorial [Hot Topic: Protein Peptide Informatics and Drug Designing - Some Computational Techniques for Structural Genomics Based Approaches (Part II) (Guest Editor: Rajani R. Joshi)]
Protein & Peptide Letters Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Combining Quantum-Behaved PSO and K2 Algorithm for Enhancing Gene Network Construction
Current Bioinformatics Selection of Targets for Drug Development Against Protozoan Parasites
Current Drug Targets